Healthcare | August 03, 2021
Meddo acquires Doxper in a cash and stock deal
This deal makes Meddo, one of the largest health-tech players in India
This deal makes Meddo, one of the largest health-tech players in India
Drug formulations and biologics make impressive gains
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Price band in the range of Rs 933 to Rs 954
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Subscribe To Our Newsletter & Stay Updated
